{"Clinical Trial ID": "NCT03210220", "Intervention": ["INTERVENTION 1:", "Group Pecs", "The needle is advanced on the tissue plane between the main pectoralis muscle and the minor pectoralis muscle near the pectoral branch of the acromiothoracic artery, and 10 ml of 0.5% ropivacaine deposited. Similarly, 20 ml is deposited on the third rib between the minor pectoralis muscle and the anterior serratus muscle.", "INTERVENTION 2:", "Monitoring Group", "There's no block."], "Eligibility": ["Incorporation criteria:", "American Society of Anesthesiologists( ASA) I or II Planned for breast cancer surgery", "- Exclusion criteria:", "Local anesthetic sensitivity, Bleeding disorders, Receptive anticoagulant, Body mass index (BMI) > 35/kg/m2, Deformation of spine or chest wall, Pregnancy"], "Results": ["Performance measures:", "Intraoperative consumption of remifentanil", "Intraoperative consumption of remifentanil during surgery (full intraoperative period)", "Duration: full intraoperative period", "Results 1:", "Title of the arm/group: Pecs Group", "Description of the arm/group: The ultrasonic-guided pectoral nerve block is performed just after induction, prior to surgery. The needle is advanced towards the tissue plane between the major pectoralis muscle and the minor pectoral muscle near the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% of the deposited ropivacaine. Similarly, 20 mL is deposited at the third rib between the minor pectoral muscle and the anterior serratus muscle.", "Total number of participants analysed: 19", "Average (standard deviation)", "Unit of measurement: \u03bcg/kg/h 6.75 (2.18)", "Results 2:", "Title of arm/group: Control group", "Description of the arm/group: There is no block.", "Total number of participants analysed: 20", "Average (standard deviation)", "Unit of measurement: \u03bcg/kg/h 10.12 (3.68)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/19 (0.00 per cent)", "Adverse Events 2:", "Total: 0/20 (0.00 %)"]}